Every figure is the balance as filed. Each filing badge opens the SEC index page for that fiscal year.
Structure
Capital structure
Assets plotted against the liabilities and equity stack, so you can see how the balance sheet is financed.
Liabilities and equity stack to the capital base; assets are the dashed reference line.
Composition
Capital mix
The same split read as a share of total capital rather than in absolute dollars.
Percentages are measured against total capital for each fiscal year.
Trend
Multi-year momentum
How assets, liabilities and equity have moved across the annual balance sheet window.
Switching between bar and line keeps the selected year order.
Doing some research...
Commentary
Commentary on LIGAND PHARMACEUTICALS INCORPORATED Balance Sheet
This explanation uses an earlier data snapshot or evidence version. Compare its generation date with the current filing figures.
Earlier AI snapshot · Generated Jun 14, 2026. The filing-backed figures above are the current source of truth.
Ligand Pharmaceuticals’ balance sheet shows a generally stronger equity position over the five-year period, but with meaningful volatility in scale. Total assets fell sharply from $1.30 billion in 2021 to $762.7 million in 2022, then stabilized and grew modestly in 2023 and 2024 before jumping materially to $1.56 billion in 2025. That latest increase suggests a significant expansion in the asset base, likely reflecting acquisitions, investment activity, or a large increase in cash/investment holdings rather than organic balance-sheet growth alone.
Liabilities moved in the opposite direction for most of the period: they declined from $476.4 million in 2021 to just $86.3 million in 2023, indicating a much lighter leverage profile and improved financial flexibility. Liabilities then ticked up to $111.3 million in 2024 before rising more sharply to $543.4 million in 2025, which is the most notable change in the series. Stockholders’ equity rose steadily from $597.5 million in 2022 to $830.4 million in 2024 and then to $1.02 billion in 2025, showing that the company maintained and expanded its net asset position despite the increase in obligations.
Overall, Ligand appears to have transitioned from a relatively low-liability balance sheet in 2022–2024 to a much larger and more levered position in 2025. For a specialty biopharma company like Ligand, such swings can be consistent with licensing, acquisition, or capital allocation activity, since the industry often uses a mix of cash, deal-related assets, and financing to support growth. The key takeaway is that equity remains comfortably positive and has grown over time, but the sharp rise in both assets and liabilities in 2025 warrants attention because it likely reflects a strategic change in the company’s financial structure.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.
